Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas
暂无分享,去创建一个
[1] P. Castro,et al. Schwannoma: A rare cause of false-positive 68Ga-PSMA PET/CT uptake in the evaluation of metastatic prostate cancer , 2021, Urology case reports.
[2] M. Sungur,et al. STAT3, VEGF, and PSMA Expression Patterns in Malignant Peripheral Nerve Sheath Tumors, Malignant Melanomas, and Glioblastomas: Does Staining Percentage and Intensity Have an Effect on Survival? , 2022, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[3] Steffie M. B. Peters,et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[4] S. Usmani,et al. Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker. , 2021, Clinical nuclear medicine.
[5] H. Moch,et al. What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[6] C. Gündoğan,et al. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma? , 2020, Clinical nuclear medicine.
[7] W. Oyen,et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[8] M. Yadav,et al. 177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. , 2020, Clinical nuclear medicine.
[9] C. Buchpiguel,et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.
[10] L. Królicki,et al. Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[11] A. Agrawal,et al. Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer. , 2020, Clinical nuclear medicine.
[12] A. Maes,et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy , 2020, The Journal of Nuclear Medicine.
[13] J. Wunder,et al. Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models , 2019, Cancers.
[14] S. Inanır,et al. 68Ga-PSMA PET/CT in Giant Retroperitoneal Liposarcoma. , 2019, Clinical nuclear medicine.
[15] W. Oyen,et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[16] R. Boellaard,et al. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone , 2019, The Journal of Nuclear Medicine.
[17] U. Lützen,et al. Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma , 2019, Nuklearmedizin.
[18] P. Flamen,et al. Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer. , 2019, Clinical nuclear medicine.
[19] M. Sydes,et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.
[20] S. Probst,et al. Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT. , 2019, Clinical nuclear medicine.
[21] A. Afaq,et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma. , 2019, Clinical nuclear medicine.
[22] Rajender Kumar,et al. 68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma. , 2019, Clinical nuclear medicine.
[23] Rajender Kumar,et al. Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT. , 2018, Clinical nuclear medicine.
[24] H. Hieronymus,et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.
[25] A. Sasikumar,et al. 68Ga-PSMA PET/CT in Osteosarcoma in Fibrous Dysplasia. , 2017, Clinical nuclear medicine.
[26] M. Vendelbo,et al. Subcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.
[27] K. Rahbar,et al. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST , 2016, Oncotarget.
[28] P. Thomas,et al. Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma. , 2016, Clinical nuclear medicine.
[29] G. Schembri,et al. Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.
[30] P. Dileo,et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.
[31] A. Okawa,et al. How Long Should We Follow Patients With Soft Tissue Sarcomas? , 2014, Clinical orthopaedics and related research.
[32] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[33] C. Stiller,et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.
[34] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[35] Chao Zeng,et al. Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma , 2012, Medical Oncology.
[36] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[37] A. Chinnaiyan,et al. Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases , 2009, Clinical Cancer Research.
[38] Sam S. Chang. Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.
[39] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[40] M. van Glabbeke,et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] N. Nowak,et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. , 1998, Biochimica et biophysica acta.